Business, energy, technology, markets and global industry news from Business News Today

neuroscience

PharmaDeviceNews neuroscience
Pharma & Biotech

Why Lilly is betting on peripheral pain biology with the 4E Therapeutics acquisition

Find out how Lilly’s 4E Therapeutics deal could advance non-opioid chronic pain drugs and what risks remain.

Read More
Representative image showing a sleep medicine consultation as Takeda’s oveporexton data highlight a potential shift in narcolepsy type 1 care.
Pharma & Biotech

Takeda’s narcolepsy data reveal why orexin agonists are becoming a neuroscience priority

Find out how Takeda’s oveporexton data could reshape narcolepsy type 1 care as approval, safety and access questions loom.

Read More
Representative image showing neuroscience-based psychiatric treatment research as Evecxia Therapeutics builds the case for EVX-101 as a potential adjunctive therapy for patients with depression, obsessive-compulsive disorder and inadequate SSRI response.
Pharma & Biotech

Can Evecxia Therapeutics turn EVX-101 into the first serotonin synthesis amplification therapy?

EVX-101 revives serotonin synthesis as an SSRI add-on strategy. Can Evecxia prove old biology still has new clinical value?

Read More
Pharma & Biotech

Neurocrine Biosciences strengthens INGREZZA case with functional improvement data

Mild TD can still disrupt work and independence. Neurocrine’s INGREZZA data raises pressure to rethink when treatment begins.

Read More
Features & Analysis

Can Teva Pharmaceutical Industries Ltd.’s Home Ground platform reshape schizophrenia support beyond medication?

Read how Teva Pharmaceutical Industries Ltd.’s Home Ground may reshape schizophrenia support, adherence, and care pathways. Discover what changes next.

Read More